Endocrine Abstracts

Proton pump inhibitor (PPI) drugs which are used safely to treat peptic ulcus disease since 2 decades, moderately increases gastrin hormone by decreasing gastric acid secretion. Preclinical studies show that gastrin itself, or drugs that increase gastrin levels such as PPIs, increase islet cell mass and improve glycaemic control. To the best of our knowledge one prospective and some retrospective studies claim that PPI medication in diabetic patients leads to an average decrease of % 0.5–0.8 in HbA1c. According to UKPDS a 1% decrease in HbA1c prevent microvascular complication by 37%. Therefore, we aimed to investigate the effect of PPI drugs on microvascular complications in a sample of patients applied to a university outpatient clinic. The PPI treated group enrolled 37 patients, while the non-PPI group consisted of 51 patients. Selected PPI using patients were treated at least for 5 years in intervals with various PPIs. The mean PPI use duration was 11.3±4.5 (6–24) months. The non-PPI group did not use any PPI longer than 1 month intervals in the last 5 years. All statistical comparisons were made by adjusting both groups according to age, diabetes duration, and mean HbA1c. Mean ages in the PPI and non-PPI group were 68.1±9.9 and 67.2±8.5 respectively (P=0.57). Mean diabetes duration in the PPI and non-PPI group were 11.1±8.5 and 9.2±4.1 respectively (P=0.13). Mean HbA1c percentages in the PPI and non-PPI group were 6.9±1.1 and 6.9±1.2 respectively (P=0.79). Mean follow-up duration of the whole study population was 48.6±36.9 (6–139) months with a median of 4 (2–7) HbA1c measurements per se. Microvascular complication rates are shown in Table 1. We conclude that although neuropathy rate was insignificantly lower on PPI, the use of PPIs does not affect microvascular complication rates in diabetic populations.